Abstract
Nebivolol (Nomexor) is a third generation, vasodilating beta-blocker with a high beta(1)-adrenoceptor selectivity. Nebivolol acts as an agonist at the beta(3) adrenoceptor as well as the estrogen receptor thereby releasing nitric oxide in blood vessels via eNOS. Pleiotropic effects of nebivolol furthermore include a positive influence on cholesterol and triglycerides and a decrease in thrombocyte activity. Nebivolol is recommended in the guidelines of the European cardiac society (ESC) for patients with metabolic syndrome. Nebivolol's main properties in combination with its broad range of beneficial pleiotropic effects allow it to be clearly distinguished from other second and third generation beta-blockers.
MeSH terms
-
Adrenergic beta-Agonists / adverse effects
-
Adrenergic beta-Agonists / classification
-
Adrenergic beta-Agonists / therapeutic use*
-
Aged
-
Aged, 80 and over
-
Animals
-
Apoptosis / drug effects
-
Benzopyrans / adverse effects
-
Benzopyrans / classification
-
Benzopyrans / therapeutic use*
-
Blood Pressure / drug effects
-
Cell Division / drug effects
-
Endothelium-Dependent Relaxing Factors / blood
-
Ethanolamines / adverse effects
-
Ethanolamines / classification
-
Ethanolamines / therapeutic use*
-
Humans
-
Hypertension / blood
-
Hypertension / drug therapy
-
Lipids / blood
-
Metabolic Syndrome / blood
-
Metabolic Syndrome / drug therapy*
-
Mice
-
Nebivolol
-
Nitric Oxide / blood
-
Platelet Aggregation / drug effects
-
Randomized Controlled Trials as Topic
-
Research
-
Vascular Resistance / drug effects
-
Vasodilator Agents / adverse effects
-
Vasodilator Agents / classification
-
Vasodilator Agents / therapeutic use*
Substances
-
Adrenergic beta-Agonists
-
Benzopyrans
-
Endothelium-Dependent Relaxing Factors
-
Ethanolamines
-
Lipids
-
Vasodilator Agents
-
Nebivolol
-
Nitric Oxide